Last reviewed · How we verify

Camrelizumab and Apatinib — Competitive Intelligence Brief

Camrelizumab and Apatinib (Camrelizumab and Apatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination PD-1 (camrelizumab); VEGFR2 (apatinib) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Camrelizumab and Apatinib (Camrelizumab and Apatinib) — Chinese Academy of Medical Sciences. Camrelizumab blocks PD-1 to enhance immune response while apatinib inhibits VEGFR2 to suppress tumor angiogenesis, combining immunotherapy with anti-angiogenic effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Camrelizumab and Apatinib TARGET Camrelizumab and Apatinib Chinese Academy of Medical Sciences phase 3 PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination PD-1 (camrelizumab); VEGFR2 (apatinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-1 inhibitor + VEGFR2 tyrosine kinase inhibitor combination class)

  1. Chinese Academy of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Camrelizumab and Apatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/camrelizumab-and-apatinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: